European Urology

Viewing slides 1-6 of 8

• S0302-2838(13)00134-6.title drag remove slide sort drag into slide Title INDIUM-111 LABELED GIRENTUXIMAB IMMUNOSPECT AS A DIAGNOSTIC TOOL IN CLEAR CELL RENAL CELL CARCINOMA
  
  CONSTANTIJN H.J. MUSELAERS, OTTO C. BOERMAN, EGBERT OOSTERWIJK, JOHANNES F. LANGENHUIJSEN, WIM ... INDIUM-111 LABELED GIRENTUXIMAB IMMUNOSPECT AS A DIAGNOSTIC TOOL IN CLEAR CELL RENAL CELL ... Zoom
• S0302-2838(13)00134-6.introduction drag remove slide sort drag into slide Introduction • Increased identification of renal masses of unknown origin due to increased use of high resolution CT frequently poses urologists for a diagnostic dilemma.
  
  • The high and specific ... • Increased identification of renal masses of unknown origin due to increased use of high ... Zoom
• 24607 drag remove slide sort drag into slide Posterior 111In-girentuximab image of Patient 14 with a small renal mass in the ... Zoom read this article »
• 24609 drag remove slide sort drag into slide Carbonic anhydrase IX (CAIX) expression in a type 2 papillary tumor. CAIX ... Zoom read this article »
• 24611 drag remove slide sort drag into slide Images from Patient 29, who had a history of clear cell renal cell carcinoma. ... Zoom read this article »
• S0302-2838(13)00134-6.materials_and_methods drag remove slide sort drag into slide Materials and methods • Twenty-nine patients received 100-200 MBq 111In-labeled girentuximab. Whole body and SPECT images were acquired after 4-7 days. • Twenty-nine patients received 100-200 MBq 111In-labeled girentuximab. Whole body and SPECT ... Zoom

Viewing slides 1-6 of 8